Vermillion Downgraded by Canaccord to Hold Rating

May 24, 2018

|

NEW YORK (360Dx) – Following Vermillion's disappointing first quarter financial results, investment bank Canaccord Genuity today downgraded the company's shares to a Hold rating from a previous Buy rating.

Canaccord also cut its price target on Vermillion's shares to $1 from $2.25.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Vermillion Downgraded by Canaccord to Hold Rating

To read the full story....

Breaking News

Biden Administration Funds $1B for COVID-19 Testing in Indian Country

Scope Fluidics Gets CE Mark for Rapid MRSA MDx Panel

NIH Awards Qorvo Biotechnologies $24.4M for Rapid SARS-CoV-2 Antigen Test

In Brief This Week: Exact Sciences, Siemens Healthineers, Seegene, Agilent Technologies, and More

Color Health, Yale Get FDA Emergency Use Authorization for Coronavirus Sample Collection Kits

Veracyte Preliminary Q1 Revenues Up 16 to 19 Percent, CFO to Retire

What's Popular?

With Luminex Acquisition, DiaSorin to Broaden MDx Portfolio, Expand US Presence

Color Health, Yale Get FDA Emergency Use Authorization for Coronavirus Sample Collection Kits

Thermo Fisher Scientific Gets FDA EUA for High-Throughput, Automated COVID-19 Test Kit

Siemens Healthineers Gets CE Mark for Point-of-Care High-Sensitivity Cardiac Troponin I Test

Antelope Dx Collaborates With In The Pocket, Extra Horizon to Develop Self-Tests

Sponsorships